Biostar Pharmaceuticals, Inc.
BSPM
BSPM was delisted on the 18th of September, 2018.
8 hedge funds and large institutions have $697K invested in Biostar Pharmaceuticals, Inc. in 2016 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 1 closing their positions.
243% more capital invested
Capital invested by funds: $203K → $697K (+$494K)
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
33% more funds holding
Funds holding: 6 → 8 (+2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$64.9K |
| 2 |
Jane Street
New York
|
+$34.7K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$8.55K |
| 4 |
AIM
Acrospire Investment Management
Chicago,
Illinois
|
+$4.46K |
| 5 |
Renaissance Technologies
New York
|
+$2.45K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1K |
| 2 |
Morgan Stanley
New York
|
-$9 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $468K | +$2.45K | +1,100 | +1% |
|
|
CS
2
Credit Suisse
Zurich,
Switzerland
| $129K | +$64.9K | +29,116 | New |
|
|
3
Jane Street
New York
| $69K | +$34.7K | +15,556 | New |
|
|
4
UBS Group
Zurich,
Switzerland
| $21K | +$8.55K | +3,839 | +402% |
|
|
AIM
5
Acrospire Investment Management
Chicago,
Illinois
| $9K | +$4.46K | +2,000 | New |
|
6
Bank of America
Charlotte,
North Carolina
| $1K | – | – | – |
|
|
TRCT
7
Tower Research Capital (TRC)
New York
| – | -$1K | -749 | Closed |
|
|
8
Morgan Stanley
New York
| – | -$9 | -4 | -14% |
|
9
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | +$2 | +1 | +100% |
|
BSPM Hedge Fund Activity: Q2 2016 in Review
8 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Biostar Pharmaceuticals, Inc. (BSPM) for Q2 2016, worth a combined $697K — up 243% from $203K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new BSPM positions and 1 closed out — a net gain of 2 holders — while 3 added to existing stakes and 1 trimmed.
The largest buyer was Credit Suisse, opening a new position worth an estimated $64.9K. The largest seller was Tower Research Capital (TRC), exiting entirely with an estimated $1K sold.
- 8 institutional investors held Biostar Pharmaceuticals, Inc. (BSPM) as of Q2 2016, up from 6 in Q1 2016.
- Funds reported $697K of Biostar Pharmaceuticals, Inc. stock for Q2 2016, up 243% quarter-over-quarter.
- 3 funds opened new Biostar Pharmaceuticals, Inc. positions in Q2 2016 and 1 closed out, a net change of +2 holders.
- The largest Biostar Pharmaceuticals, Inc. buyer in Q2 2016 was Credit Suisse, an estimated $64.9K added.
- The largest Biostar Pharmaceuticals, Inc. seller in Q2 2016 was Tower Research Capital (TRC), an estimated $1K sold.
Based on aggregated 13F filings for Q2 2016.